Cargando…

COVID-19 vaccines: Update of the vaccines in use and under development

The ongoing COVID-19 pandemic has imposed a series of challenges on the scientific community. One of the biggest was the development of safe and effective vaccines in record time, which could be achieved through a global effort. A topic of great discussion has been the technology surrounding these v...

Descripción completa

Detalles Bibliográficos
Autores principales: Marta, Rafaela Angotti, Nakamura, Gisele Emy Kondo, de Matos Aquino, Bruno, Bignardi, Paulo R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier España, S.L.U. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683840/
http://dx.doi.org/10.1016/j.vacune.2022.11.007
_version_ 1784835141427789824
author Marta, Rafaela Angotti
Nakamura, Gisele Emy Kondo
de Matos Aquino, Bruno
Bignardi, Paulo R.
author_facet Marta, Rafaela Angotti
Nakamura, Gisele Emy Kondo
de Matos Aquino, Bruno
Bignardi, Paulo R.
author_sort Marta, Rafaela Angotti
collection PubMed
description The ongoing COVID-19 pandemic has imposed a series of challenges on the scientific community. One of the biggest was the development of safe and effective vaccines in record time, which could be achieved through a global effort. A topic of great discussion has been the technology surrounding these vaccines: ranging from the well-known inactivated virus vaccines to the latest RNA vaccines. As vaccines became available, another point also came into question: their efficacy and effectiveness against the original Wuhan strain and its variants. Among the numerous variants, 5 of them (Alpha, Beta, Gamma, Delta and, more recently, Omicron) gained greater prominence due to their epidemiological relevance. In this scenario, with numerous variants and several vaccine options, scientific information can often be mismatched. This review aims to provide an overview of the efficacy, effectiveness, and safety of 11 vaccines in use or under development against the original Wuhan strain and the variants of concern identified by the World Health Organisation (WHO). Simultaneously, we aim to explore possible scenarios that can be expected shortly regarding new variants and vaccines. Overall, COVID-19 vaccines have satisfactory efficacy and loss of effectiveness against SARS-CoV-2 variants, especially the Omicron strain.
format Online
Article
Text
id pubmed-9683840
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier España, S.L.U.
record_format MEDLINE/PubMed
spelling pubmed-96838402022-11-25 COVID-19 vaccines: Update of the vaccines in use and under development Marta, Rafaela Angotti Nakamura, Gisele Emy Kondo de Matos Aquino, Bruno Bignardi, Paulo R. Vacunas (English Edition) Review Article The ongoing COVID-19 pandemic has imposed a series of challenges on the scientific community. One of the biggest was the development of safe and effective vaccines in record time, which could be achieved through a global effort. A topic of great discussion has been the technology surrounding these vaccines: ranging from the well-known inactivated virus vaccines to the latest RNA vaccines. As vaccines became available, another point also came into question: their efficacy and effectiveness against the original Wuhan strain and its variants. Among the numerous variants, 5 of them (Alpha, Beta, Gamma, Delta and, more recently, Omicron) gained greater prominence due to their epidemiological relevance. In this scenario, with numerous variants and several vaccine options, scientific information can often be mismatched. This review aims to provide an overview of the efficacy, effectiveness, and safety of 11 vaccines in use or under development against the original Wuhan strain and the variants of concern identified by the World Health Organisation (WHO). Simultaneously, we aim to explore possible scenarios that can be expected shortly regarding new variants and vaccines. Overall, COVID-19 vaccines have satisfactory efficacy and loss of effectiveness against SARS-CoV-2 variants, especially the Omicron strain. Published by Elsevier España, S.L.U. 2022 2022-11-24 /pmc/articles/PMC9683840/ http://dx.doi.org/10.1016/j.vacune.2022.11.007 Text en © 2022 Published by Elsevier España, S.L.U. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Marta, Rafaela Angotti
Nakamura, Gisele Emy Kondo
de Matos Aquino, Bruno
Bignardi, Paulo R.
COVID-19 vaccines: Update of the vaccines in use and under development
title COVID-19 vaccines: Update of the vaccines in use and under development
title_full COVID-19 vaccines: Update of the vaccines in use and under development
title_fullStr COVID-19 vaccines: Update of the vaccines in use and under development
title_full_unstemmed COVID-19 vaccines: Update of the vaccines in use and under development
title_short COVID-19 vaccines: Update of the vaccines in use and under development
title_sort covid-19 vaccines: update of the vaccines in use and under development
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683840/
http://dx.doi.org/10.1016/j.vacune.2022.11.007
work_keys_str_mv AT martarafaelaangotti covid19vaccinesupdateofthevaccinesinuseandunderdevelopment
AT nakamuragiseleemykondo covid19vaccinesupdateofthevaccinesinuseandunderdevelopment
AT dematosaquinobruno covid19vaccinesupdateofthevaccinesinuseandunderdevelopment
AT bignardipaulor covid19vaccinesupdateofthevaccinesinuseandunderdevelopment